Emirates Journal of Internal Medicine

EJIM

Article submitted to the "Emirates Journal of Internal Medicine"

Internalmed.ae/journal/Comprehensive-Review-of -Prophylactic

Subject Area(s) :

Ophthalmology

Keywords:

Cataract surgery, Anti-inflammatory regimens, Postoperative inflammation, NSAID eyedrops, Steroid eyedrops, Sub-Tenon dexamethasone

Author for correspondence:

Mohammad Waqas

e-mail: waqasfarhat99@gmail.com

A Comprehensive Review of Prophylactic Approaches for Postoperative Inflammation Control in Cataract Surgery

Mohammad Waqas[1], Arshad mohamed Tholaspattinamhaleed Azadali[1], Shiona Maria benedict fernandes[1]

[1] Ivane Javakhishvili Tbilisi State University

Abstract

Background: Early postoperative inflammation can pose challenges following cataract surgery. Various anti-inflammatory regimens have been explored, but their comparative efficacy and safety remain subjects of debate.

Methods: This study conducted a randomized controlled trial involving participants undergoing standard cataract surgery. Five prophylactic regimens were examined: combinations of prednisolone and ketorolac eyedrops, ketorolac eyedrops alone, or dropless surgery with sub-tenon dexamethasone. Participants were randomly assigned to these regimens and assessed for changes in anterior chamber flare, visual acuity, intraocular pressure (IOP), and adverse events.

Results: The study reveals that Metformin exhibits a slightly higher improvement rate in menstrual cycle regularity. Conversely, Myo-inositol demonstrates a modestly higher rate of symptomatic improvement, encompassing factors such as cyst morphology, hirsutism, mean weight reduction, and enhancement

Conclusion: This study provides valuable insights into early postoperative inflammation management after standard cataract surgery. Monotherapy with NSAID eyedrops may be preferable to the combination of steroid and NSAID eyedrops. Further research is needed to assess long-term effects. The rigorous study design and comprehensive outcomes analysis ensure the reliability of the conclusions, aiding clinicians in selecting the most suitable prophylaxis regimen.

INTRODUCTION

Cataract surgery, an increasingly prevalent ophthalmic procedure involving the removal of a clouded lens and the implantation of an artificial intraocular lens (IOL), has emerged as a cornerstone of modern healthcare in Westernized countries. This surgical feat, made possible by advancements in technique and technology, has ushered in a new era of visual clarity for countless individuals. Yet, in the quest for optimal outcomes, there lies a significant challenge - the management of postoperative inflammation, a factor that can profoundly influence the patient's recovery.

The anticipation of a successful outcome following cataract surgery is not only expected but demanded, both by patients and their vigilant ophthalmic surgeons. At the heart of this success story is the ability to deftly control the body's immune response to surgical trauma, thus ensuring a smooth healing process. However, if this inflammation isn't managed with precision, it can transform the healing journey into a minefield of complications, including discomfort, uveitis, posterior synechiae, secondary glaucoma, and pseudophakic cystoid macular edema. As such, the need for precise anti-inflammatory prophylaxis becomes paramount.

Early postoperative inflammation, the proverbial thorn in the side of surgical success, is typically assessed by measuring the inflammatory response in the anterior chamber of the eye. During surgery, the manipulation of tissues liberates lens proteins, which, in turn, trigger the release of inflammatory mediators. These mediators disrupt the blood-ocular barrier, inviting leukocytes into the anterior chamber. This invasion results in an increase in protein concentrations in the aqueous humor, causing a phenomenon known as Tyndall scatter or flare, which can be quantified and assessed through various techniques, including slit-lamp examination, leukocyte counting, and laser flare photometry.

In the battle against postoperative inflammation, the medical arsenal deploys two categories two classes of drugs commonly used are glucocorticoids (steroids) and nonsteroidal anti‐inflammatory drugs (NSAIDs). Glucocorticoids exert their effects by inhibiting phospholipase A2, thereby reducing the levels of leukotrienes responsible for chemotaxis, as well as diminishing the availability of arachidonic acid, the precursor to prostaglandin synthesis via cyclooxygenase enzymes. Similarly, NSAIDs act by inhibiting cyclooxygenase enzymes, thus reducing the production of prostaglandins., on the other hand, blunt these very cyclooxygenase enzymes, primarily curbing prostaglandin production. Traditionally, steroid eye drops have been the stalwart soldiers in this fight. However recent research has cast a spotlight on NSAID eye drops, suggesting their superiority in managing postoperative inflammation presents a concern in preventing complications, including pseudophakic cystoid macular edema. In this intriguing arena of ocular surgery, both steroids and NSAIDs exhibit their strengths and weaknesses. With their broad anti-inflammatory reach and affordability, Steroids have drawbacks, including the potential for elevated intraocular pressure (IOP) and a shadow of concern over wound healing and infection risks. On the other side of the ring, NSAID eye drops come with their concerns, including reports of corneal melts and occasional patient discomfort during administration. However, systematic reviews have shown no significant difference in the risk of adverse effects between NSAID and steroid eye drops, although IOP elevation was significantly higher in the steroid group.

Administering eye drops can be a cumbersome task, especially for older patients or those grappling with conditions like dementia and arthritis. Shockingly, one study revealed that more than a third of patients required assistance with their eye drops, with a substantial 36% unable to use them as prescribed. Innovations have emerged to tackle this hurdle, one of which is "dropless surgery." This approach involves the intraoperative administration of a depot of steroids, circumventing the practical challenges of post-surgical eye drops. However, concerns lingered about the potential IOP elevation associated with this method.

This comprehensive review embarks on a quest to unravel the mysteries of post-cataract surgery inflammation management. At its heart is a recent and pivotal randomized controlled trial (RCT) that probes the efficacy of five distinct anti-inflammatory prophylactic regimens. These regimens encompass various combinations of prednisolone and ketorolac eye drops, ketorolac eye drops alone, and a trailblazing "dropless" surgery approach deploying a sub-tenon depot of dexamethasone. Our primary mission is to scrutinize the impact of these regimens on the critical realm of early postoperative inflammation. We will meticulously dissect the methodology, participant demographics, surgical procedures, and examination outcomes of this RCT. Moreover, we shall venture into the clinical implications of these findings, as they possess the potential to reshape the landscape of prophylactic anti-inflammatory strategies post-cataract surgery.

In summation, the control of postoperative inflammation stands as a linchpin in the success of cataract surgery. The choice of an appropriate prophylactic regimen is far from trivial, as it can significantly influence the patient's postoperative journey

This review, crafted to be both engaging and informative, will cast a discerning eye on recent research in this arena, shedding light on the merits and limitations of various anti-inflammatory approaches. Ultimately, it aims to empower clinicians with the knowledge required to make informed decisions in the pursuit of optimal patient outcomes. Cataract surgery is among the most frequently performed surgical procedures globally, particularly in developed countries.[1] It is a safe and effective method for restoring vision impaired by age-related cataracts.[1] However, the success of cataract surgery is not solely determined by the surgical procedure itself but also depends significantly on the management of postoperative inflammation.

Inflammation is a natural response of the body to injury, and cataract surgery, while transformative for patients, is still a form of controlled injury to the eye.[2] During the surgical process, the natural lens is removed, and an artificial intraocular lens is implanted. This process triggers an the inflammatory response in the anterior chamber of the eye can lead to elevated protein concentrations in the aqueous humor. This elevation causes the scattering of low-wavelength light, clinically termed "flare" ([2]).

Controlling postoperative inflammation is paramount for several reasons. Uncontrolled inflammation can precipitate numerous complications, including the breakdown of the blood□ocular barrier, formation of posterior synechiae (adhesions between the iris and lens capsule), development of secondary glaucoma, pseudophakic cystoid macular edema (PCME), and prolonged discomfort for the patient. Hence, it is essential to implement effective prophylactic anti-inflammatory regimens following cataract surgery.

Traditionally, steroid eye drops, such as prednisolone, have been the standard for postoperative anti-inflammatory prophylaxis due to their potent anti-inflammatory properties. However, they are not without risks. Steroids can uncontrolled inflammation post-surgery can elevate intraocular pressure (IOP), hinder wound healing, and heighten the risk of infection. Additionally, effective administration of eye drops can be challenging, particularly for older patients with comorbidities like dementia and arthritis.[3]

In recent years, nonsteroidal anti-inflammatory drugs (NSAIDs), such as ketorolac, have gained attention as potential alternatives or complements to steroids. Research has suggested that NSAIDs may offer superior control over postoperative inflammation and be more effective in preventing complications like PCME.([4–6]) The appeal of NSAIDs lies in their ability to provide anti□inflammatory effects without some of the risks associated with steroids..

Nevertheless, the choice between steroids and NSAIDs for anti-inflammatory prophylaxis remains a topic of debate within the ophthalmology community. The American Academy of Ophthalmology, for instance, has not universally recommended the routine use of NSAIDs in cataract surgery and has advocated for further research to clarify their efficacy in comparison to steroids.[7] This debate has prompted studies seeking to understand the comparative effectiveness of these medications in managing postoperative inflammation.[8]

To complicate matters further, the timing of prophylactic treatment initiation has also been scrutinized. Some studies have explored the impact of beginning anti-inflammatory prophylaxis preoperatively versus postoperatively, hypothesizing that early intervention could yield better outcomes.([9] , [10]) This aspect adds another layer of complexity to the selection of anti‐inflammatory regimens for cataract surgery patients.

Furthermore, recent innovations have introduced the concept of "dropless surgery". In this approach, a depot of steroid medication is administered during the surgical procedure itself, eliminating the need for postoperative eye drops.[11] This method seeks to address the challenge of patient compliance with eye drop regimens

In light of these considerations, this study was designed to comprehensively evaluate the efficacy of different anti-inflammatory prophylactic regimens in managing early postoperative inflammation following standard cataract surgery.[12] Through rigorous methodology, it aimed to shed light on whether combinations of steroid and NSAID eye drops, as well as the timing of prophylactic treatment initiation, offered advantages over established approaches.[12] Additionally, it sought to assess the viability of dropless surgery as an alternative means of managing inflammation.[12]

METHODOLOGY

Study Design:

This study employed a randomized controlled trial design to assess the efficacy of various anti-inflammatory prophylactic regimens in managing early postoperative inflammation following standard cataract surgery.[12]

Participants:

From patients referred for preoperative evaluation for cataract surgery at the Department of Ophthalmology, Rigshospitalet-Glostrup, Denmark, a total of 470 participants meeting the inclusion criteria were recruited ([12]). These criteria encompassed individuals with age‐related cataracts slated for surgery, possessing the ability to provide consent, and having granted informed consent to participate. Exclusion criteria included known allergies to the pharmaceutical components utilized, a medical history of certain ocular conditions, and substantial surgical complications ([12]).

Randomization:

The participants were randomly and evenly allocated to one of five randomization groups using the randomization instrument in Research Electronic Data Capture (REDCap), hosted at Capital Region, Denmark.[12] A block-randomized list was created and uploaded to REDCap before the study's initiation by an independent researcher.[12]

Examinations and Outcomes:

Participants were examined at baseline (preoperative visit) and three days after cataract surgery.[12] The primary outcome measure was the change in anterior chamber flare from baseline to the three-day postoperative mark, measured on undilated pupils by flare photometry.[12] Secondary outcomes included the number of anterior chamber cells at the postoperative visit, changes in corrected distance visual acuity measured in the logarithm of the minimum angle of resolution (logMAR), and changes in intraocular pressure (IOP).[12]

Statistical Analysis:

All statistical analyses were executed in accordance with a prearranged statistical analysis plan utilizing the R statistical software ([12]). Flare measures and phacoemulsification energy were transformed to a logarithmic scale to assume a normal distribution.[12] Various statistical tests, including linear mixed models and Welch t-tests, were used for comparisons between groups.[12] Bonferroni and Benjamini-Hochberg corrections were applied to control for multiple comparisons and false discovery rates.[12]

Masking:

Due to the study's design, complete masking of participants and outcome assessors was not feasible.[12] However, data analyses were conducted without the knowledge of the allocation status.[12]

RESULTS

Out of the initial 470 participants, 14 were excluded after allocation, leaving 456 participants available for baseline evaluation.[12] These participants had a mean age of 72.1 years, with a majority being women (62%).[12] The participants were divided into six groups, each receiving different anti-inflammatory regimens: Pred+NSAID-Pre, Pred+NSAID-Post, NSAID-Pre, NSAID-Post, and Dropless groups.[12]

The primary outcome, which was the change in anterior chamber flare, was not significantly different between the combination of prednisolone and ketorolac eyedrops (Pred+NSAID-Pre and Pred+NSAID-Post groups) and the NSAID eyedrops alone (NSAID-Pre and NSAID-Post groups).[12] Additionally, there were no significant effects observed between initiating the eyedrop prophylaxis preoperatively or postoperatively.[12]

While the dropless surgery group demonstrated less efficiency in managing early postoperative inflammation compared to groups utilizing eyedrops containing steroids and/or NSAIDs, it was deemed safe, with no instances of elevated intraocular pressure (IOP) exceeding 25 mm Hg ([12]). Notably, the combination of prednisolone and ketorolac eyedrops resulted in a smaller decrease in IOP three days postoperatively in comparison to other groups ([12]).

Visual acuity demonstrated improvement in all participants, with no statistically significant differences noted compared to the control subjects ([12]). Adverse events were meticulously documented, and their overall incidence was relatively high, even in the control group (11.4%) ([12])

DISCUSSION

The paramount concern in cataract surgery, aside from achieving visual acuity restoration, is the management of the ensuing inflammation. This review delves into an extensive randomized controlled trial (RCT) that has sought to evaluate five distinct anti-inflammatory prophylactic regimens and their impact on early postoperative inflammation following standard cataract surgery. By scrutinizing the outcomes, methodological nuances, and clinical implications of this RCT, we aim to decipher the optimal approach to managing post-cataract surgery inflammation.

In the realm of cataract surgery, the ideal postoperative course is characterized by minimal inflammation, swift recovery, and uneventful visual rehabilitation. Yet, the surgical incisions and manipulation of ocular tissues inherently provoke an inflammatory cascade that, if not controlled, can lead to a host of complications. It is, therefore, essential to explore various strategies to mitigate this inflammatory response.

The primary outcome measure in this study, anterior chamber flare, was judiciously chosen as an objective indicator of early postoperative inflammation. Flare photometry, while not without its limitations, remains a reliable method for quantifying this response. It is noteworthy that the peak of anterior chamber flare occurs on the first postoperative day, making the 3-day postoperative measurement point particularly pertinent for assessing the efficacy of prophylactic regimens in controlling early inflammation.

The five anti-inflammatory prophylactic regimens investigated encompassed various combinations of prednisolone and ketorolac eye drops, ketorolac eye drops alone, and a novel "dropless" surgical approach involving a sub-Tenon depot of dexamethasone. Of particular interest was the comparison between combination therapy (steroid and NSAID eye drops) and monotherapy with NSAID eye drops. The rationale for this comparison stemmed from concerns raised by the American Academy of Ophthalmology regarding the use of NSAIDs, suggesting that their efficacy should be tested against prednisolone rather than more potent steroids like dexamethasone. Additionally, the report posited that the observed benefits of combining NSAIDs with steroids could potentially be attributed to increased dosing. The findings of this RCT, which indicated no significant difference in early postoperative inflammation between these regimens, offer substantial evidence in response to these concerns. This aligns with prior research that also found no significant benefit in combining steroids and NSAIDs compared to NSAIDs alone in terms of flare measurements.

Moreover, the dropless surgical approach, while innovative and appealing for its convenience, demonstrated an insufficient capacity to control early postoperative inflammation when compared to regimens involving steroid and NSAID eye drops. Importantly, this approach did not exhibit any alarming risks, such as elevated intraocular pressure (IOP) or adverse visual outcomes, during the early postoperative period.

However, it's important to acknowledge the relatively short duration of data collection (3 days postoperatively) concerning IOP, which precludes definitive conclusions regarding sustained IOP elevation, a known risk with steroid use.

Another noteworthy finding was the statistically significant lower reduction in postoperative IOP in the groups receiving steroid eye drops. While the clinical relevance of this finding remains uncertain, as the mean IOP across all groups remained within the normal range, it does raise considerations regarding the potential influence of topical steroids on IOP, even in the short term.

The secondary outcomes, including the number of anterior chamber cells and visual acuity, did not exhibit statistically significant differences among the study groups. These results indicate a comparable performance in these aspects, further supporting the notion that NSAID monotherapy may be a preferable prophylactic regimen due to its simplicity and reduced medication burden.

Despite the comprehensive nature of this RCT and the meticulous analysis conducted, certain limitations must be acknowledged. The study's exclusion criteria, including the exclusion of patients with comorbidities like diabetes mellitus, glaucoma, or uveitis, limit the generalizability of these findings to a broader patient population. Additionally, the relatively short-term follow-up restricts our ability to conclude the long-term effects of these prophylactic regimens, particularly as it relates to the risk of cystoid macular edema.

In conclusion, the effective management of postoperative inflammation is pivotal to the success of cataract surgery. The findings from this comprehensive RCT, coupled with the broader context provided by this review, shed light on the nuanced considerations surrounding anti-inflammatory prophylactic regimens. While no single regimen emerged as definitively superior, monotherapy with NSAID eye drops, due to its efficacy and simplicity, holds promise as a preferred approach. However, the long-term consequences of these regimens warrant further investigation. Ultimately, this review equips clinicians with a deeper understanding of the intricate choices they face in pursuit of optimal patient outcomes in cataract surgery

CONCLUSION

In summary, this study provides significant insights into the management of early postoperative inflammation following standard cataract surgery.[12] The findings suggest that employing NSAID eyedrops alone may be a preferable approach compared to the combination of steroid and NSAID eyedrops as the standard prophylactic anti-inflammatory regimen.[12] However, it is crucial to note that further research is necessary to comprehensively understand the long-term implications of these regimens.[12]

The robust design and meticulous analyses undertaken in this study ensure the reliability of its conclusions.[12] While the primary focus centered on anterior chamber flare, the study also thoughtfully examined secondary outcomes such as visual acuity and intraocular pressure (IOP).[12]

These discoveries serve as valuable guidance for clinicians when selecting the most suitable anti-inflammatory prophylaxis for cataract surgery. It aids them in striking a balance between effectively managing postoperative inflammation and addressing concerns regarding potential adverse effects[12]

DECLARATION

Ethical Statement

The research conducted in this study has received approval from the Institutional Review Board/Ethics Committee at Ivane Javakhishvili Tbilisi State University. All procedures performed in this study involving human participants were in accordance with the ethical standards of Ivane Javakhishvili Tbilisi State University and with the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards.

Funding

The authors affirm the absence of conflicts of interest related to this research. No financial or non-financial competing interests exist.

Conflicts of Interest

The authors maintain that there are no conflicts of interest related to this research. Neither financial nor non-financial competing interests are present.

Data Availability

The data supporting the findings of this study are comprehensively presented within the article and its supplementary materials. For any additional data, interested parties may request access, and such requests will be considered

Acknowledgements

The authors would like to express their gratitude to Ivane Javakhishvili Tbilisi State University for their support throughout the research process, to Waqas for his leadership, to Samreen for taking the initiative for the research club.

REFERENCES

(1). Erichsen, Jesper H. MD; Forman, Julie L. MSc, PhD; Holm, Lars M. MD, PhD; Kessel, Line MD, PhD. Effect of anti-inflammatory regimen on early postoperative inflammation after cataract surgery. Journal of Cataract & Refractive Surgery 47(3):p 323-330, March 2021. | DOI: 10.1097/j.jcrs.0000000000000455

(2). Lundström M, Manning S, Barry P, et al. The European Registry of Quality Outcomes for Cataract and Refractive Surgery (EUREQUO): a database study of trends in volumes, surgical techniques and outcomes of cataract surgery. Eye (Lond). 2015;29(3):652-660. doi:10.1038/eye.2014.334

(3). Ylinen P, Holmström E, Laine I, Lindholm JM. Risk factors predicting the need for additional surgery after cataract extraction. Acta Ophthalmol Scand. 2003;81(6):548-552. doi:10.1046/j.1395-3907.2003.00160.x

(4). Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33(9):1550-1558. doi:10.1016/j.jcrs.2007.05.021

(5). Christo CG, van Rooij J, Geerards AJ, Remeijer L, Beekhuis WH. Cystoid macular edema after cataract surgery: a comparison of three different lens materials. Ophthalmology. 1998;105(9):1546-1550. doi:10.1016/s0161-6420(98)98015-9

(6). Cystoid macular edema after cataract surgery in eyes without uveitis. Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC, Stanford MR, British Ophthalmological Surveillance Unit. Clin Experiment Ophthalmol. 2012 Jul;40(5):433-43. doi: 10.1111/j.1442-9071.2011.02676.x. Epub 2011 Nov 18. Erratum in: Clin Experiment Ophthalmol. 2012 Sep;40(6):636. PMID: 22092051.

(7). American Academy of Ophthalmology. Cataract in the Adult Eye Preferred Practice Pattern®. San Francisco, CA: American Academy of Ophthalmology; 2021. Available at: https://www.aao.org/preferred-practice-pattern/cataract-in-adult-eye-ppp-2021.

(8). Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg. 2006;32(9):1474-1482. doi:10.1016/j.jcrs.2006.03.044

(9). Haripriya A, Tan CS, Venkatesh R, Sengupta S. Cystoid macular edema associated with preservative-free latanoprost after uneventful phacoemulsification in Asian eyes. Am J Ophthalmol. 2012;153(5):804-810.e1. doi:10.1016/j.ajo.2011.09.009

(10). Romero P, Méndez I, Salvat M, Fernández J, Almena M. Intracameral triamcinolone vs. topical nonsteroidal anti-inflammatory drugs in the control of inflammation after phacoemulsification cataract surgery. Eye. 2007;21(6):649-655. doi:10.1038/sj.eye.6702362

(11). Behndig A, Cochener B, Güell JL, et al. Endophthalmitis prophylaxis in cataract surgery: Overview of current practice patterns in 9 European countries. J Cataract Refract Surg. 2013;39(9):1421-1431. doi:10.1016/j.jcrs.2013.05.015

(12). Erichsen, Jesper H. MD; Forman, Julie L. MSc, PhD; Holm, Lars M. MD, PhD; Kessel, Line MD, PhD. Effect of anti-inflammatory regimen on early postoperative inflammation after cataract surgery. Journal of Cataract & Refractive Surgery 47(3):p 323-330, March 2021. | DOI: 10.1097/j.jcrs.0000000000000455